![]() ![]() “The backlogs caused by the pandemic and industrial actions mean that fast-paced technology like this can really be the difference between life and death. The turnaround time with Digistain is much quicker, it is more accurate and cheaper. Sharaz Khan, NHS head of pathology at the Northampton General Hospital, which is an early adopter of Digistain, said: "Digistain cuts down wait times for results massively when compared to our current provider who is sending samples to the US for analysis. ![]() It has also gained support from breast cancer survivor and patient advocate, actress Samantha Womack who has called for its adoption by the NHS and was selected as one of the Top 10 clinical studies of the year by the American Society Of Breast Surgery. It is being trialled by several UK NHS trusts. UK-invented Digistain is currently being adopted around the world by hospitals in India, Thailand, Ecuador, Vietnam, Singapore, Malaysia, Myanmar and Indonesia, with deals in the US and parts of Africa imminent. “The results indicate that Digistain can lead to statistically significant cumulative savings of an average of £286.7 million for an intermediate-risk patient population once rolled out as a substitute.” The innovation proves to be more cost-effective for post-menopausal women. ![]() Digistain proves to be an optimal alternative to the currently offered tumour profiling test, as it delivers non-inferior health outcomes while generating cost savings…Implementing Digistain as a substitute for the current care would lead to improved health outcomes. The health economic study concluded: “The results indicate that the greatest cost savings can be achieved by offering Digistain as a substitute. The 40-page study found that Digistain’s technology eliminates this need, therefore reducing the NHS carbon footprint by 460 tonnes.ĭigistain has been inducted into the NHS Innovation Accelerator programme - mandated to help innovations spread throughout the NHS quickly.Ĭlinical data unveiled at the American Society of Clinical Oncology in Chicago last month showed that Digistain demonstrated similar diagnostic accuracy to the current National Institute for Health and Care Excellence-approved cancer test. Most breast cancer biopsy results are currently air freighted to the US for analysis at huge cost to the NHS - and the environment. If the tool was utilised for other areas of cancer across the NHS it would offer even greater savings. The health economic study, carried out by Health Tech Connect and commissioned and funded by the UK government, concluded that the AI-powered tool would present huge savings in healthcare with much lower acquisition costs, transportation fees and a reduced prescription of chemotherapy, by as much as 30%. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |